Intratumoral Cancer Therapies Market Anticipated to Grow at 11.7% CAGR Through 2029: Industry Report
The Business Research Company
The Business Research Company's Intratumoral Cancer Therapies Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, November 24, 2025 /EINPresswire.com/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors
How Big Is The Intratumoral Cancer Therapies Market In 2025?
The market size of intratumoral cancer treatments has seen a rapid expansion in the last few years. It's set to increase from $140 billion in 2024 to $156.96 billion in 2025, representing a compound annual growth rate (CAGR) of 12.1%. The impressive growth during the historic period can be credited to advancements in cancer research, rising incidence of cancer, the demand for precision medicine, strong clinical evidence and research initiatives, as well as unresolved medical needs.
Anticipations are high for a swift expansion in the intratumoral cancer therapies market in the coming few years. The projections suggest a growth to ""$243.95 billion in 2029"", marking a compound annual growth rate (CAGR) of 11.7%. This anticipated expansion in the forthcoming period is predominantly credited to breakthroughs in immunotherapy, the escalating prevalence of precision medicine, expansion of clinical trials, increased attention to rare types of cancer and regulatory endorsements. The upcoming trends to lookout for incorporate the probe into intratumoral immunomodulators, the incorporation of image-guided therapies, the utilization of hyperthermia in intratumoral treatments, clinical trials of combined therapies, and regulatory backing for intratumoral therapies.
Download a free sample of the intratumoral cancer therapies market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9979&type=smp
What Are The Key Driving Factors For The Growth Of The Intratumoral Cancer Therapies Market?
The escalating prevalence of cancer is anticipated to boost the expansion of the intratumoral cancer therapies market in the future. Cancer is an array of conditions marked by the unrestrained proliferation and distribution of abnormal cells within the body. Intratumoral cancer treatments, which help evade off-target toxicities, dose-limiting toxicities, and destructive effects caused by immune stimulation, are utilized in the diagnosis and treatment of cancer. For instance, in January 2023, as per the American Cancer Society, a nonprofit cancer advocacy institution based in the US, a rise of 3.16% from 1,898,160 in 2021 was recorded with the cancer cases surging to 1,958,310 in 2023. Consequently, this accelerating prevalence of cancer is the driving force behind the growth of the intratumoral cancer therapies market.
Who Are The Key Players In The Intratumoral Cancer Therapies Industry?
Major players in the Intratumoral Cancer Therapies include:
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• Eli Lilly and Company
• F. Hoffmann-la Roche
• Takeda Pharmaceutical Company Ltd.
What Are The Upcoming Trends Of Intratumoral Cancer Therapies Market In The Globe?
Advancements in technology are becoming a prominent trend within the intratumoral cancer therapies market. Firms in this sector are embracing novel technologies to maintain market dominance. For instance, Evonik, an American specialty chemical production company, pioneered a cutting-edge microparticle technology named EUDRATEC SoluFlow in March 2022. This technology is aimed at enhancing the solubility of active pharmaceutical ingredients in oral medicine formulations for cancer treatments. This innovative solution enables previously believed to be insoluble compounds to be incorporated into a broader range of oral drugs.
What Segments Are Covered In The Intratumoral Cancer Therapies Market Report?
The intratumoral cancer therapies market covered in this report is segmented –
1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines
2) By Application: Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head And Neck Cancer, Other Applications
3) By End Users: Hospitals, Cancer Research Centers, Clinics
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
3) By Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors
4) By Cell Therapies: CAR T-Cell Therapy, TCR Therapy
5) By Immune System Modulators: Immune Checkpoint Inhibitors, Toll-Like Receptor Agonists
6) By Adoptive Cell Transfer: Tumor-Infiltrating Lymphocytes (TILs), Peripheral Blood Lymphocytes (PBLs)
7) By Cytokines: Interleukins, Interferons, Tumor Necrosis Factor (TNF)
View the full intratumoral cancer therapies market report:
https://www.thebusinessresearchcompany.com/report/intratumoral-cancer-therapies-global-market-report
Which Region Is Expected To Lead The Intratumoral Cancer Therapies Market By 2025?
In 2024, North America led the market for intratumoral cancer therapies. The market report on intratumoral cancer therapies covered the following regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
Browse Through More Reports Similar to the Global Intratumoral Cancer Therapies Market 2025, By The Business Research Company
Cancer Biologics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report
Cancer Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Tumor Ablation Therapy Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
